Patents by Inventor Hajar Mohammed ALZAHRANI

Hajar Mohammed ALZAHRANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating leukemia
    Patent number: 10639382
    Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: May 5, 2020
    Assignees: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Services, King Abdullah International Medical Research Center
    Inventors: Mohamed Boudjelal, Atef Nehdi, Ahmed Sulaiman Alaskar, Imadul Islam, Hajar Mohammed Alzahrani
  • METHOD OF TREATING LEUKEMIA
    Publication number: 20180296692
    Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 18, 2018
    Applicants: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
    Inventors: Mohamed BOUDJELAL, Atef NEHDI, Ahmed Sulaiman ALASKAR, lmadul ISLAM, Hajar Mohammed ALZAHRANI